Report

TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF ASIA PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET 39
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 CURRENCY AND PRICING 46
2.5 DBMR TRIPOD DATA VALIDATION MODEL 47
2.6 MULTIVARIATE MODELLING 50
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.8 DBMR MARKET POSITION GRID 52
2.9 MARKET APPLICATION COVERAGE GRID 53
2.10 VENDOR SHARE ANALYSIS 54
2.11 SECONDARY SOURCES 55
2.12 ASSUMPTIONS 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 64
4.1 PORTER'S FIVE FORCES 65
4.2 PESTEL ANALYSIS 66
4.2.1 POLITICAL FACTORS 66
4.2.2 ECONOMIC FACTORS 67
4.2.3 SOCIAL FACTORS 67
4.2.4 TECHNOLOGICAL FACTORS 68
4.2.5 ENVIRONMENTAL FACTORS 68
4.2.6 LEGAL FACTORS 68
4.2.7 QUALITY ASSURANCE & POST MARKET OBLIGATIONS 69
4.3 PATENT ANALYSIS 70
4.3.1 PATENT NUMBER AND EXPIRY 70
4.3.2 COUNTRY-LEVEL APPROVAL 70
4.3.3 LIST OF PRODUCTS REACHING EXPIRY IN NEXT 3 YEARS 71
4.3.4 DRUGS PATENT IN SPECIFIC COUNTRIES 71
4.4 COMPANY EVALUATION QUADRANT 73
4.5 SUPPLY CHAIN ECOSYSTEM 74
4.5.1 PROMINENT COMPANIES 74
4.5.2 SMALL & MEDIUM SIZE COMPANIES 74
4.5.3 END USERS 74
4.6 TOP TESTS RANKING & MARKET OPPORTUNITY SECTION 76
4.6.1 CHINA 76
4.6.2 JAPAN 76
4.6.3 INDIA 77
4.6.4 SOUTH KOREA 77
4.6.5 SINGAPORE 77
4.6.6 MALAYSIA 77
4.6.7 THAILAND 77
4.6.8 INDONESIA 77
4.6.9 PHILIPPINES 77
4.6.10 VIETNAM 78
4.6.11 REST OF ASIA-PACIFIC 78
4.7 CUSTOMER BUYING DRIVERS - QUALITY, ASP, SPEED, REPUTATION OTHERS 79
4.7.1 QUALITY 79
4.7.2 AVERAGE SELLING PRICE (ASP) 79
4.7.3 SPEED 80
4.7.4 REPUTATION 80
4.7.5 OTHER INFLUENTIAL FACTORS 80
4.8 INDUSTRY INSIGHTS 81
4.8.1 MICRO AND MACRO ECONOMIC FACTORS 81
4.8.2 MICROECONOMIC FACTORS 81
4.8.3 MACROECONOMIC FACTORS 81
4.8.4 PENETRATION AND GROWTH PROSPECT MAPPING 82
4.8.5 MARKET PENETRATION & GROWTH BY COUNTRY 82
4.8.6 BASED ON MODE (TYPE OF RAPID DIAGNOSTIC TEST) 83
4.8.7 BASED ON DIAGNOSTIC APPROACH 83
4.8.8 BASED ON END?USER 84
4.9 KEY PRICING STRATEGIES 85
4.9.1 STRATEGIC PRICING APPROACHES FOR RDTS IN APAC 85
4.9.2 INTERVIEWS WITH SPECIALIST 85
4.9.3 MARKET PENETRATION AND TECHNOLOGY ADOPTION 86
4.10 GROWTH DRIVERS AND CHALLENGES 86
4.10.1 PRICING AND PROCUREMENT 86
4.10.2 END-USER PREFERENCES AND INSIGHTS 86
4.10.3 STRATEGIC IMPLICATIONS DERIVED FROM SPECIALIST INSIGHTS: 86
4.10.4 ANALYSIS AND RECOMMENDATION 87
4.10.5 MARKET ANALYSIS 87
4.10.6 STRATEGIC RECOMMENDATIONS 87
4.10.7 CONCLUSION 87
5 REGULATORY FRAMEWORK 88
5.1 REGULATORY APPROVAL PROCESS 88
5.2 GENERAL PROCESS STEPS (APAC): 88
5.3 VARIATIONS BY MARKET 88
5.4 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 88
5.5 REGULATORY APPROVAL PATHWAYS 89
5.6 STANDARD APPROVAL PATHWAY 89
5.7 RELIANCE / ABRIDGED APPROVAL PATHWAY 89
5.8 EXPEDITED / PRIORITY REVIEW PATHWAY 89
5.9 EMERGENCY USE AUTHORIZATION (EUA) 90
5.10 COUNTRY-SPECIFIC PATHWAY OVERVIEW 90
5.11 LICENSING AND REGISTRATION 90
5.12 INDIA - CDSCO LICENSING & REGISTRATION 90
5.13 SINGAPORE - HEALTH SCIENCES AUTHORITY (HSA) 91
5.14 AUSTRALIA - THERAPEUTIC GOODS ADMINISTRATION (TGA) 92
5.15 OTHER APAC MARKETS (SUMMARY) 92
5.16 POST-MARKETING SURVEILLANCE 94
5.17 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 95
6 EPIDEMIOLOGY 97
6.1 INCIDENCE OF ALL BY GENDER 97
6.2 TREATMENT RATE 97
6.3 MORTALITY RATE 98
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 98
6.5 PATIENT TREATMENT SUCCESS RATES 99
7 HEALTHCARE TARIFFS IMPACT ANALYSIS 100
7.1 OVERVIEW 100
7.2 TARIFF STRUCTURES. 100
7.2.1 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 100
7.2.2 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 100
7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 100
7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 100
7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 101
7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 101

7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 101
7.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 101
7.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 101
7.4.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 101
7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 102
7.5.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 102
7.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 102
7.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 102
7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 102
7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 102
8 MARKET OVERVIEW 103
8.1 DRIVERS 105
8.1.1 RISING DISEASE BURDEN AND EXPANDING HEALTHCARE ACCESS 105
8.1.2 INCREASING ADOPTION OF LATERAL FLOW ASSAY AND IMMUNOLOGY BASED RAPID TEST 105
8.1.3 INTEGRATION OF DIGITAL HEALTH PLATFORM WITH RAPID DIAGNOSTICS FOR RESULT TRACKING 106
8.1.4 INCREASING GOVERNMENT INITIATIVES AND FUNDING FOR HEALTHCARE SCREENING PROGRAMS 107
8.2 RESTRAINTS 108
8.2.1 HIGH COST OF ADVANCED RAPID DIAGNOSTIC TESTS (RDT) 108
8.2.2 SHORT SHELF LIFE AND STRINGENT STORAGE CONDITIONS OF (RDTS) 109
8.3 OPPORTUNITIES 110
8.3.1 TECHNOLOGICAL ADVANCEMENTS DRIVING ACCURACY AND ACCESSIBILITY 110
8.3.2 GROWTH POTENTIAL IN PANDEMIC PREPAREDNESS AND OUTBREAK SURVEILLANCE PROGRAM 111
8.3.3 GROWING OVER-THE-COUNTER (OTC) CONSUMER ADOPTION AND RETAIL DISTRIBUTION GROWTH 112
8.4 CHALLENEGS 113
8.4.1 REGULATORY BARRIERS AND QUALITY ASSURANCE CONCERNS 113
8.4.2 INCONSISTENT QUALITY STANDARDS AMONG LOW-COST TEST MANUFACTURERS 114
9 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE 115
9.1 OVERVIEW 116
9.2 PROFESSIONAL RAPID DIAGNOSTIC TEST - VISUAL READ 120
9.3 OTC (OVER-THE-COUNTER) RAPID DIAGNOSTIC TEST 120
9.4 PROFESSIONAL RAPID DIAGNOSTIC TEST - INSTRUMENT READ 120
9.5 PROFESSIONAL RAPID MOLECULAR DIAGNOSTIC TEST - INSTRUMENT READ 120
?
10 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY 121
10.1 OVERVIEW 122
10.2 LABORATORY BASED TEST 125
10.3 NON-LABORATORY BASED TEST 125
11 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP 126
11.1 OVERVIEW 127
11.2 ADULT 130
11.3 PEDIATRICS 130
12 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DIAGNOSTIC APPROACH 131
12.1 OVERVIEW 132
12.2 IN-VITRO DIAGNOSTIC (IVD) - IMMUNOASSAY / LATERAL FLOW 135
12.3 MOLECULAR DIAGNOSTIC (MD) 135
12.4 ASIA-PACIFIC IN-VITRO DIAGNOSTIC (IVD) - IMMUNOASSAY / LATERAL FLOW IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 135
12.4.1 LATERAL FLOW IMMUNOASSAY (LFIA) 135
12.4.2 VISUAL READ RDTS (CASSETTE/STRIP FORM) 135
12.4.3 COLORIMETRIC 136
12.4.4 OTHERS 136
12.5 ASIA-PACIFIC MOLECULAR DIAGNOSTIC (MD) IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 136
12.5.1 NAAT-BASED RAPID 136
12.5.2 RAPID PCR 136
12.5.3 ISOTHERMAL AMPLIFICATION 136
12.5.4 OTHERS 137
13 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION AREA 138
13.1 OVERVIEW 139
13.2 INFECTIOUS DISEASE TESTING 143
13.3 ASIA-PACIFIC INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 143
13.3.1 RESPIRATORY INFECTION TESTS 143
13.3.2 HEPATITIS 143
13.3.3 HIV 144
13.3.4 MALARIA 144
13.3.5 DENGUE 144
13.3.6 SEXUALLY TRANSMITTED DISEASES 144
13.3.7 GASTROINTESTINAL INFECTIONS 144
13.3.8 CHIKUNGUNYA 144
13.3.9 OTHERS 144
13.4 ASIA-PACIFIC RESPIRATORY INFECTION TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 145
13.4.1 INFLUENZA A+B / A+B+C 145
13.4.2 RSV 145
13.4.3 STREP A 145
13.4.4 MYCOPLASMA 145
13.4.5 S. PNEUMONIA 146
13.4.6 LEGIONELLA 146
13.4.7 OTHERS 146
13.5 ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 146
13.5.1 CHLAMYDIA 146
13.5.2 GONORRHEA 146
13.5.3 SYPHILIS 147
13.5.4 OTHERS 147
13.6 ASIA-PACIFIC INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 147
13.6.1 H. PYLORI AB/AG 147
13.6.2 TYPHOID 148
13.6.3 ROTAVIRUS 148
13.6.4 C. DIFFICILE 148
13.6.5 E. COLI 148
13.6.6 NOROVIRUS 148
13.6.7 CAMPYLOBACTER 148
13.6.8 ADENOVIRUS 148
13.6.9 E71 148
13.6.10 OTHERS 148
13.7 CARDIOLOGY TESTING 149
13.8 ASIA-PACIFIC CARDIOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 149
13.8.1 HS-TROPONIN I 149
13.8.2 BNP / NT PROBNP 150
13.8.3 D DIMER 150
13.8.4 S-TROPONIN T 150
13.8.5 CK MB 150
13.8.6 HSCRP 150
13.8.7 MYOGLOBIN 150
13.8.8 PCT 150
13.8.9 ST2 150
13.8.10 HOMOCYSTEINE 150
13.8.11 GALECTIN 3 151
13.9 PREGNANCY & FERTILITY TESTING 151
13.10 ASIA-PACIFIC PREGNANCY & FERTILITY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 151
13.10.1 HCG 151
13.10.2 LH 151
13.10.3 COMBINED FERTILITY PANELS 151
13.11 DRUGS OF ABUSE TESTING 152
13.12 ASIA-PACIFIC DRUGS OF ABUSE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 152
13.12.1 MULTI-PANEL URINE TESTS 152
13.12.2 ORAL FLUID DRUG TESTS 152
13.13 ONCOLOGY TESTING 152
13.14 ASIA-PACIFIC ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 153
13.14.1 AFP 153
13.14.2 CEA 153
13.14.3 PSA 153
13.14.4 CA19 9 153
13.14.5 CA125 154
13.14.6 CA15 3 154
13.14.7 OTHERS 154
13.15 COAGULATION TESTING 154
13.16 ASIA-PACIFIC COAGULATION TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 154
13.16.1 PT 154
13.16.2 PTT 155
13.16.3 ACT 155
13.16.4 FIB 155
13.16.5 TT 155
13.17 OTHERS 155
14 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRICE RANGE 156
14.1 OVERVIEW 157
14.2 ECONOMY 160
14.3 MID-RANGE 160
14.4 PREMIUM 160
?
15 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER 161
15.1 OVERVIEW 162
15.2 HOSPITALS & CLINICS 165
15.3 ASIA-PACIFIC HOSPITALS & CLINICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND) 165
15.3.1 PUBLIC 165
15.3.2 PRIVATE 165
15.4 DIAGNOSTIC LABORATORIES 165
15.5 HOME CARE SETTINGS 165
15.6 RESEARCH & ACADEMIC INSTITUTES 166
15.7 OTHERS 166
16 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY BUSINESS TYPE 167
16.1 OVERVIEW 168
16.2 GOVERNMENT SECTOR 171
16.3 PRIVATE SECTOR 171
17 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY COUNTRY 172
17.1 ASIA-PACIFIC 172
17.1.1 CHINA 186
17.1.2 JAPAN 197
17.1.3 INDIA 208
17.1.4 SOUTH KOREA 219
17.1.5 AUSTRALIA 230
17.1.6 INDONESIA 241
17.1.7 THAILAND 252
17.1.8 SINGAPORE 263
17.1.9 MALAYSIA 274
17.1.10 PHILIPPINES 285
17.1.11 VIETNAM 296
17.1.12 PAKISTAN 307
17.1.13 BANGLADESH 318
17.1.14 SRI LANKA 329
17.1.15 NEPAL 339
17.1.16 AFGHANISTAN 349
17.1.17 MALDIVES 359
17.1.18 BHUTAN 369
17.1.19 REST OF ASIA-PACIFIC 379
?
18 GERMANY SAFETY FOOTWEAR MARKET, COMPANY LANDSCAPE 390
18.1 ASIA-PACIFIC RAPID DIAGNOSTIC TESTS (RDT) COMPANY SHARE ANALYSIS: ASIA-PACIFIC 390
18.2 COMPANY SHARE ANALYSIS BY MODE 391
18.2.1 PROFESSIONAL RAPID DIAGNOSTIC TEST - VISUAL READ 391
18.2.2 PROFESSIONAL RAPID DIAGNOSTIC TEST - INSTRUMENT READ 392
18.2.3 PROFESSIONAL RAPID MOLECULAR DIAGNOSTIC TEST - INSTRUMENT READ 393
18.2.4 OTC (OVER-THE-COUNTER) RAPID DIAGNOSTIC TEST 394
19 SWOT ANALYSIS 395
20 COMPANY PROFILE 396
20.1 F. HOFFMANN-LA ROCHE LTD 396
20.1.1 COMPANY SNAPSHOT 396
20.1.2 REVENUE ANALYSIS 396
20.1.3 PRODUCT PORTFOLIO 397
20.1.4 RECENT DEVEOPMENT 399
20.2 ABBOTT 400
20.2.1 COMPANY SNAPSHOT 400
20.2.2 REVENUE ANALYSIS 400
20.2.3 PRODUCT PORTFOLIO 401
20.2.4 RECENT DEVEOPMENT 402
20.3 SYSMEX CORPORATION 403
20.3.1 COMPANY SNAPSHOT 403
20.3.2 REVENUE ANALYSIS 403
20.3.3 PRODUCT PORTFOLIO 404
20.3.4 RECENT DEVEOPMENT 405
20.4 DANAHER CORPORATION 406
20.4.1 COMPANY SNAPSHOT 406
20.4.2 REVENUE ANALYSIS 407
20.4.3 PRODUCT PORTFOLIO 407
20.4.4 RECENT DEVELOPMENT 411
20.5 THERMO FISHER SCIENTIFIC 413
20.5.1 COMPANY SNAPSHOT 413
20.5.2 REVENUE ANALYSIS 414
20.5.3 PRODUCT PORTFOLIO 414
20.5.4 RECENT DEVEOPMENT 415
20.6 ACCESS BIO 416
20.6.1 COMPANY SNAPSHOT 416
20.6.2 PRODUCT PORTFOLIO 416
20.6.3 RECENT DEVELOPMENT 417
20.7 BECTON, DICKINSON (BD) 418
20.7.1 COMPANY SNAPSHOT 418
20.7.2 REVENUE ANALYSIS 418
20.7.3 PRODUCT PORTFOLIO 419
20.7.4 RECENT DEVEOPMENT 420
20.8 BIOGENIX INC. PVT. LTD. 421
20.8.1 COMPANY SNAPSHOT 421
20.8.2 PRODUCT PORTFOLIO 421
20.8.3 RECENT DEVELOPMENT 421
20.9 BIOSCI HEALTHCARE 422
20.9.1 COMPANY SNAPSHOT 422
20.9.2 PRODUCT PORTFOLIO 422
20.9.3 RECENT DEVELOPMENT 423
20.10 BIOMERIEUX 424
20.10.1 COMPANY SNAPSHOT 424
20.10.2 REVENUE ANALYSIS 424
20.10.3 PRODUCT PORTFOLIO 425
20.10.4 RECENT DEVEOPMENT 426
20.11 BIO-RAD LABORATORIES, INC. 427
20.11.1 COMPANY SNAPSHOT 427
20.11.2 REVENUE ANALYSIS 427
20.11.3 PRODUCT PORTFOLIO 428
20.11.4 RECENT DEVELOPMENT 430
20.12 CHEMBIO DIAGNOSTICS, INC. 432
20.12.1 COMPANY SNAPSHOT 432
20.12.2 PRODUCT PORTFOLIO 432
20.12.3 RECENT DEVELOPMENT 433
20.13 FUJIREBIO 435
20.13.1 COMPANY SNAPSHOT 435
20.13.2 PRODUCT PORTFOLIO 435
20.13.3 RECENT DEVEOPMENT 436
20.14 GENBODY INC. 437
20.14.1 COMPANY SNAPSHOT 437
20.14.2 PRODUCT PORTFOLIO 437
20.14.3 RECENT DEVELOPMENT 438
20.15 INTEC PRODUCTS, INC. 439
20.15.1 COMPANY SNAPSHOT 439
20.15.2 PRODUCT PORTFOLIO 439
20.15.3 RECENT DEVELOPMENT 440

20.16 J. MITRA & CO. PVT. LTD. 441
20.16.1 COMPANY SNAPSHOT 441
20.16.2 PRODUCT PORTFOLIO 441
20.16.3 RECENT DEVELOPMENT 442
20.17 MERIL DIAGNOSTICS 443
20.17.1 COMPANY SNAPSHOT 443
20.17.2 PRODUCT PORTFOLIO 443
20.17.3 RECENT DEVELOPMENT 446
20.18 PRECISION BIOMED PVT LTD. 447
20.18.1 COMPANY SNAPSHOT 447
20.18.2 PRODUCT PORTFOLIO 447
20.18.3 RECENT DEVELOPMENT 447
20.19 QIAGEN 448
20.19.1 COMPANY SNAPSHOT 448
20.19.2 REVENUE ANALYSIS 448
20.19.3 PRODUCT PORTFOLIO 449
20.19.4 RECENT DEVEOPMENT 450
20.20 QUIDELORTHO CORPORATION 451
20.20.1 COMPANY SNAPSHOT 451
20.20.2 REVENUE ANALYSIS 452
20.20.3 PRODUCT PORTFOLIO 452
20.20.4 RECENT DEVELOPMENT 455
20.21 SD BIOSENSOR, INC. 456
20.21.1 COMPANY SNAPSHOT 456
20.21.2 REVENUE ANALYSIS 456
20.21.3 PRODUCT PORTFOLIO 457
20.21.4 RECENT DEVELOPMENT 458
20.22 SIEMENS HEALTHINEERS 459
20.22.1 COMPANY SNAPSHOT 459
20.22.2 REVENUE ANALYSIS 459
20.22.3 PRODUCT PORTFOLIO 460
20.22.4 RECENT DEVEOPMENT 462
20.23 TRINITY BIOTECH 463
20.23.1 COMPANY SNAPSHOT 463
20.23.2 REVENUE ANALYSIS 463
20.23.3 PRODUCT PORTFOLIO 464
20.23.4 RECENT DEVEOPMENT 465
?
20.24 WERFEN 466
20.24.1 COMPANY SNAPSHOT 466
20.24.2 PRODUCT PORTFOLIO 466
20.24.3 RECENT DEVELOPMENT 467
20.25 WONDFO 468
20.25.1 COMPANY SNAPSHOT 468
20.25.2 PRODUCT PORTFOLIO 468
20.25.3 RECENT DEVELOPMENT 470
21 QUESTIONNAIRE 471
22 RELATED REPORTS 475
?